Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects
Completed
Scilex Pharmaceuticals, Inc.
Phase 1
2016-09-28
The purpose of this study is to characterize the comparative single-dose pharmacokinetics
(bioequivalence) of lidocaine patch 1.8% (investigational product) versus Lidoderm®
(lidocaine patch 5%,reference product).
Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise
Completed
Scilex Pharmaceuticals, Inc.
Phase 1
2016-01-08
The objectives of this study are to evaluate the pharmacokinetic and adhesion performance of
ZTlido (lidocaine topical system) 1.8% during physical exercise, application of heat, and
under normal conditions.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
